小儿麻痹症疫苗 "Sabin's OPV "在意大利引入 60 年后的历史:不可原谅的 "延误"。

Davide Orsini, Lucia Valchi, Carola Minet, Mariano Martini
{"title":"小儿麻痹症疫苗 \"Sabin's OPV \"在意大利引入 60 年后的历史:不可原谅的 \"延误\"。","authors":"Davide Orsini, Lucia Valchi, Carola Minet, Mariano Martini","doi":"10.15167/2421-4248/jpmh2024.65.1.3242","DOIUrl":null,"url":null,"abstract":"<p><p>In the spring of 1964, polio vaccination with the oral vaccine developed by Albert Sabin began in Italy. Polio was feared in the world and in Italy. Thus, between 1957 and the beginning of 1958, Italian children began receiving the \"Salk vaccine\", though the results were not particularly convincing. In July 1960, the international scientific community was able to verify the data from the mass testing of the Sabin vaccine. It became clear that the OPV, could prevent the virus from multiplying, thereby providing greater protection and determining the eradication of the disease. In 1960 over 70 million people in the USSR alone had already received the oral vaccine and mass vaccination in the USA would start in March 1961. However, in Italy there was no similar initiative; only later the new vaccine was accepted but was not made compulsory at the beginning. As a result of the commission's report, registration of the \"Polioral\" vaccine, was authorized in September 1962 but the sale of the vaccine was not authorized until November 1963. At the beginning of 1964, the production of \"Polioral\" started and the product was marketed and on the 1 st of March 1964, anti-polio vaccination with the \"Sabin anti-polio vaccine\" also began in Italy. This manuscript focuses on a crucial issue about a historical delay for public health and it points out as the preparation and diffusion of the Sabin polio vaccine demonstrates that decisions regarding health treatments, and specifically vaccination campaigns, must be based exclusively on the results of clinical studies and on independent evaluation by the scientific community. This process ensures trust in vaccines, adequate protection of public health andcitizens' well-being.</p>","PeriodicalId":94106,"journal":{"name":"Journal of preventive medicine and hygiene","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11066819/pdf/","citationCount":"0","resultStr":"{\"title\":\"The history of polio vaccination with \\\"Sabin's OPV\\\" 60 years after its introduction in Italy: an unforgivable \\\"delay\\\".\",\"authors\":\"Davide Orsini, Lucia Valchi, Carola Minet, Mariano Martini\",\"doi\":\"10.15167/2421-4248/jpmh2024.65.1.3242\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In the spring of 1964, polio vaccination with the oral vaccine developed by Albert Sabin began in Italy. Polio was feared in the world and in Italy. Thus, between 1957 and the beginning of 1958, Italian children began receiving the \\\"Salk vaccine\\\", though the results were not particularly convincing. In July 1960, the international scientific community was able to verify the data from the mass testing of the Sabin vaccine. It became clear that the OPV, could prevent the virus from multiplying, thereby providing greater protection and determining the eradication of the disease. In 1960 over 70 million people in the USSR alone had already received the oral vaccine and mass vaccination in the USA would start in March 1961. However, in Italy there was no similar initiative; only later the new vaccine was accepted but was not made compulsory at the beginning. As a result of the commission's report, registration of the \\\"Polioral\\\" vaccine, was authorized in September 1962 but the sale of the vaccine was not authorized until November 1963. At the beginning of 1964, the production of \\\"Polioral\\\" started and the product was marketed and on the 1 st of March 1964, anti-polio vaccination with the \\\"Sabin anti-polio vaccine\\\" also began in Italy. This manuscript focuses on a crucial issue about a historical delay for public health and it points out as the preparation and diffusion of the Sabin polio vaccine demonstrates that decisions regarding health treatments, and specifically vaccination campaigns, must be based exclusively on the results of clinical studies and on independent evaluation by the scientific community. This process ensures trust in vaccines, adequate protection of public health andcitizens' well-being.</p>\",\"PeriodicalId\":94106,\"journal\":{\"name\":\"Journal of preventive medicine and hygiene\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11066819/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of preventive medicine and hygiene\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15167/2421-4248/jpmh2024.65.1.3242\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of preventive medicine and hygiene","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15167/2421-4248/jpmh2024.65.1.3242","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

1964 年春,意大利开始使用阿尔伯特-萨宾研制的口服疫苗接种脊髓灰质炎疫苗。小儿麻痹症在全世界和意大利都引起了恐慌。因此,从 1957 年到 1958 年初,意大利儿童开始接种 "索尔克疫苗",尽管结果并不特别令人信服。1960 年 7 月,国际科学界对萨宾疫苗的大规模试验数据进行了验证。很明显,OPV 可以阻止病毒繁殖,从而提供更大的保护,并决定根除该疾病。1960 年,仅苏联就有 7 000 多万人接种了口服疫苗,美国将于 1961 年 3 月开始大规模接种。然而,意大利却没有类似的举措;只是后来才接受了新疫苗,但一开始并没有强制接种。根据委员会的报告,"Polioral "疫苗于 1962 年 9 月获准注册,但直到 1963 年 11 月才获准销售。1964 年初,"Polioral "疫苗开始生产并上市销售,1964 年 3 月 1 日,意大利也开始接种 "Sabin 抗脊髓灰质炎疫苗"。这篇手稿关注的焦点是一个有关公共卫生历史性延误的关键问题,它指出,Sabin 脊髓灰质炎疫苗的制备和推广表明,有关健康治疗,特别是疫苗接种活动的决策必须完全以临床研究结果和科学界的独立评估为基础。这一过程确保了对疫苗的信任、对公共卫生和公民福祉的充分保护。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The history of polio vaccination with "Sabin's OPV" 60 years after its introduction in Italy: an unforgivable "delay".

In the spring of 1964, polio vaccination with the oral vaccine developed by Albert Sabin began in Italy. Polio was feared in the world and in Italy. Thus, between 1957 and the beginning of 1958, Italian children began receiving the "Salk vaccine", though the results were not particularly convincing. In July 1960, the international scientific community was able to verify the data from the mass testing of the Sabin vaccine. It became clear that the OPV, could prevent the virus from multiplying, thereby providing greater protection and determining the eradication of the disease. In 1960 over 70 million people in the USSR alone had already received the oral vaccine and mass vaccination in the USA would start in March 1961. However, in Italy there was no similar initiative; only later the new vaccine was accepted but was not made compulsory at the beginning. As a result of the commission's report, registration of the "Polioral" vaccine, was authorized in September 1962 but the sale of the vaccine was not authorized until November 1963. At the beginning of 1964, the production of "Polioral" started and the product was marketed and on the 1 st of March 1964, anti-polio vaccination with the "Sabin anti-polio vaccine" also began in Italy. This manuscript focuses on a crucial issue about a historical delay for public health and it points out as the preparation and diffusion of the Sabin polio vaccine demonstrates that decisions regarding health treatments, and specifically vaccination campaigns, must be based exclusively on the results of clinical studies and on independent evaluation by the scientific community. This process ensures trust in vaccines, adequate protection of public health andcitizens' well-being.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Health equity e sostenibilità nella vaccinazione antinfluenzale degli adulti over 65 in Italia. Interaction of protein intake and number of family members as a risk factor for chronic energy deficiency in women of childbearing age. Longitudinal trends in physical activity levels and lifetime cardiovascular disease risk: insights from the ATTICA cohort study (2002-2022). Machine learning techniques to identify risk factors of breast cancer among women in Mashhad, Iran. Monitoring emergency and urgent surgery: an improvement in a Healthcare Management Unit at a third-level hospital in Italy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1